“The Artificial Synthetic Tendons & Ligaments market is estimated to be at USD 20.3 million in 2020”, says Visiongain

31 October 2019
Pharma

Artificial Synthetic Tendons & Ligaments Market Forecast 2020-2030: Forecasts and Application (Knee Injuries, Shoulder Injuries, Foot and Ankle Injuries, Spine Injuries, and Hip Injuries), End-Use (Hospitals and Clinics, Ambulatory Surgery Centers), By Material (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Polylactic-Co-Glycolic Acid (PLGA)) and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Artificial Synthetic Tendons & Ligaments sector analysis.

According to the report published by Visiongain, the Artificial Synthetic Tendons & Ligaments market is estimated to be at USD 20.3 million in 2020 and is expected to exhibit a CAGR of 11.3% over the forecast period. Increasing incidence of sports injuries is the key factor driving the market. Tendons are specialized, heterogeneous connective tissues that pose a major healthcare threat following trauma. The gold standard method of treatment is primary surgical restoration; however, it is extremely conditional on the magnitude of wounds. An option solution for excellent tissue inclusion and regeneration is tissue engineering. In this study, we glance at the sophisticated biomaterial composites used to enhance cell growth while offering suitable mechanical characteristics for the restoration of tendons and ligaments.

During the restoration of anterior cruciate bone (ACL), artificial ligaments were commonly accepted clinically in the 1980s and 1990s. Then, morbidity and disease transmission from the donor site were displayed in the restoration of ACL using allografts or autographs; on the other hand, all these adverse events could be avoided in a rebuilding surgery using prostheses. They were viewed as successful instruments with such apparent benefits. They would become efficient options to the traditional techniques of restoration of ACL if clinically embraced. In addition, the main results were very beneficial for most of these prostheses, with reduced levels of complication and excellent postoperative regeneration. Different types of synthetic ligaments were developed and introduced to hospitals based on these results; each had its own requirements for design patterns, sewing techniques, and fabric products. However, most of these prostheses were no longer used after 20 years of clinical trials due to elevated complication and error levels. However, some synthetic ligaments persisted and in hospitals, such as the Ligament Augmentation Reinforcement System (LARS) and the Leeds–Keio ligaments, were still available. Recently, new kinds of synthetic ligaments ("Neoligaments" label) have also been implemented in hospitals, including knee, shoulder, and ankle joint elastic tendons and ligaments.

Synthetic products were widely explored for tendon and ligament restoration, including polylactic acid (PLA), polyglycolic acid (PGA), and polylactic co-glycolic acid (PLGA). Synthetics have several benefits associated with large-scale production, restricted transmission of disease, regulated degradation, and greater inclusion of donor tissue. Cell incorporation is difficult without further substance therapy, degradation-related products can be cytotoxic, and the components are mechanically stronger than good musculoskeletal bodies. New tissue engineering methods using composite materials to replicate complicated, nonhomogenous settings in tendons and ligaments have also been defined. Specialized cells were coupled with biomaterials in these composite materials to create complicated, heterogeneous scaffolds with mechanical characteristics regulated. This study will give an outline of the various methods outlined for the use of composite scaffolds for the engineering of tendon and ligament tissue. A thorough review of mechanical characteristics, inclusion of cells / tissues, requirements for achievement, and constraints is discussed in depth.

 

Artificial Synthetic Tendons & Ligaments Market is witnessing Growth due to factors such as

There are currently several difficulties that need to be resolved for tendon tissue engineering. First, there is no need for a separate normal assessment to identify the mechanical demands for effective tendon regeneration. This should integrate multiple types of mechanical evaluation (including stress and rotating) with distinct methods to tissue engineering to replicate the natural environment. Due to the heterogeneous design of tendons, this is hard to accomplish and enforce. The second task is to tackle and regulate the adjacent tissue's reaction to the scaffold being implanted. To date, this has been restricted to in vitro apps observing the inherent therapeutic reaction. Furthermore, most surveys of the use of composite materials for tendon and ligament tissue engineering use tiny creatures such as rabbits rather than bigger designs such as sheep or horses. Such constraints are focused on important weight and mechanical differences between designs in vitro and indigenous animal tissues. In addition, the ability to fix the manufactured construction in situ (with suture, anchors) and the availability of shelf life should be considered when testing a model. In reality, the scaffold-tendon or scaffold-bone interaction is the location where the scaffolds themselves are at danger of rupture after implantation.

Current status in clinical application

With the growth of sophisticated biomaterials and sophisticated surgical methods with stronger surgical instruments in latest years, concern in using synthetic grafts has been rekindled in ligament reconstruction. When we start talking about the present state of synthetic ligaments in clinical apps, we need to relate to LARS, which orthopedists in China have recently kept in excellent grace. Biomechanical studies have shown that the PET-weaved LARS ligament has adequate power as a graft for restoration of ACL.

Most sport injuries are caused by accidents, inadequate facilities, bad preparation and exercise, inadequate heating and strengthening, and absence of conditioning. Among the most prevalent kinds of sport injuries found among players are ankle sprain, neck squeeze, hamstring pressure, ACL tear and tennis elbow.

In addition, a substantial proportion of individuals are ignorant of safety policies related to sports, which can lead to multiple mild to serious accidents. According to the Accident & Emergency (A&E) statistics published by the UK Parliament, an estimated 165,000 cases of sport-related injuries occurred in the departments of A&E in England in 2016.

Increasing bias for minimally invasive surgery, public projects relevant to knowledge of sport injuries, and advances in surgical procedures will also improve synthetic tendons and ligaments for knee, ankle, and tendon strengthening.

Complications such as quadriceps deficiency, tendon rupture, anterior knee pain, and lack of complete expansion are correlated with autologous and allogeneic grafts. Consequently, the dangers connected with autograft and allograft processes have spurred the creation of ligament regeneration synthetic products. Players working on the industry, as well as multiple study organisations, focus on R&D operations to discover a new product that shows no immunity response and has elevated tensile power and opposition to abrasion.

Researchers are also collaborating on developing fresh synthetic ligament grafts that can incorporate with indigenous bones, strengthen the knee, and encourage fresh tissue development. Scientists at Hokkaido University, for example, created a bendable, hard, and fiber-reinforced hydrogel biomaterial in July 2017 that can withstand daily wear and tear. The team of scientists suggested that the material can be used as an artificial ligament, artificial tendon, or artificial organs. Hence, rising R&D activities are anticipated to keep this market at high growth trajectory.

 

 

Shift in Trends

Health care providers, however, are reluctant to embrace synthetic tendons and ligaments, mainly due to their elevated costs engaged in the associated processes and adverse reimbursement situation. In addition, these synthetic tendons and ligaments are hampered by the multiple hazards, particularly that of synovial membrane swelling in nurses. The absence of qualified experts to perform surgery in less advanced areas also boosts the industry. Nevertheless, in emerging nations, the opportunities of the synthetic tendons and ligaments industry are enormous, fuelled primarily by big unmet requirements. Furthermore, growing governments’ initiatives to bolster the public’s participation in sports are also expected to catalyze the expansion of the market.

Due to the increasing incidence of anterior cruciate valve (ACL) accidents among cyclists and sportsmen, the knee injury section is expected to carry a large proportion during the forecast period. Additionally, developments in ACL-related methods that render the method more efficient will increase section development in the years to come. The other segment of apps involves hip dislocation, injury to the elbow and spinal injury. Because of their elevated achievement level, the section is expected to record important development due to increased complete femoral tumor resections and prothetic substitution processes. Cousin Biotech's NAJA and IntraSpine, Arthrex's InternalBrace, Cousin Biotech's LARS are some of the main products in this section.

It is also expected that an increasing geriatric population will fuel the section. Conditions such as fragile bodies and smooth connective tissues such as ligaments and tendons as well as cartilage wear and fall are a higher risk factor for the growth of knee-related accidents with increasing era. According to WHO, the global population aged 85 years or older is expected to increase by 351 percent between 2010 and 2050, while at the same time the population aged 65 and older will increase by 188 percent.

Growing numbers of government efforts to encourage surgical installations to enhance healthcare efficiency and deliver rapid results will further boost the section of hospitals and clinics. Another element accountable for the significant percentage taken by the section is the collaboration of important athletes and orthopedic hospitals to raise consciousness of sport injuries and available treatments.

The section of outpatient surgery facilities (ASCs) is anticipated to develop at a profitable pace during the forecast period due to an enhanced amount of ankle and shoulder-related surgeries conducted in ASCs and outpatient facilities connected to the hospital. Moreover rising awareness regarding minimal invasive surgeries will fuel segment growth in the near future.

Regional Market Analysis

As a result of increasing brand acceptance, Europe retained a significant portion of the worldwide industry in 2018, combined with a strong level of consciousness of unnatural grafts for treating multiple sport injuries. In addition, the existence in the region of important competitors will boost the industry. For example, the Corin Group distributes LARS ligaments in the UK; Xiros Ltd (UK) produces the Leeds-Keio ligament as well as the PatellarTape System and Jewel ACL products (under the Neoligaments product title). In addition, these competitors focus on expanding regional delivery networks that are expected to enhance consumer reach. Germany, France, and Great Britain. They are key markets in Europe and have provided more than 60.0 percent of income in 2018 as a result of enhanced incidence of anterior cruciate knee (ACL) ruptures in the context of enhanced involvement in athletics operations. According to an essay released in the 2017 Health Economics Review, an approximately 30,000 ACL breakdowns in hospital expenses in Germany are rebuilt each year, amounting to USD 129.61 million.

The Asia Pacific industry is expected to expand substantially over the forecast period. The industry is motivated by significant investment in research and development by important worldwide participants on the industry, as well as growing consciousness of the use of synthetic tendons and ligaments for ACL processes. Australia and Japan are well-established companies in the region, while over the forecast period, China and India are expected to record elevated development.

In the present situation, autologous, allogeneic ligaments and tendons are chosen over synthetic grafts in the U.S. for orthopedic surgery linked to knee, ankle, and spine. Moreover, the LARS artificial ligament, which is widely preferred in Canada and European countries, is not approved by the U.S. FDA. Thus, upcoming product approvals on the backdrop of ongoing clinical trials are expected to provide a platform for growth of North America market over the forecast period.

 

 

Competition in the market

The increasing incidence of sport-related accidents is probable to arise as the main pushing force for the industry, particularly in developed countries such as the U.S. and the U.K. The increasing amount of minimally invasive surgeries for the restoration of tendons and ligaments worldwide is anticipated to increase the requirement for synthetic tendons and ligaments. The increasing demand for contemporary surgical procedures that give nurses minimal pain is increasing the synthetic tendons and ligaments market's clinical opportunities. Rapid developments in knee replacement processes in developed countries are also probable to provide a large, favourable boost in the not-so-distant future for market growth.

The main competitors are Corin Group, Xiros Ltd (Neoligament), and Mathys AG Bettlach, which cumulatively controlled over 60.0 percent of the industry in 2019. These businesses are focused on extending their delivery networks and R&D installations in order to improve their geographic footprint and manufacturing ability, thus enhancing their business situation. Corin, for example, set up a fresh office and manufacturing plant in the UK in June 2018. This strategic initiative is expected to boost the production and delivery ability of the company, further supporting its development in both the local and international markets.

Emerging competitors like Cousin Biotech, BioMed, and FX Solutions focus on fund-raising operations to promote R&D development and marketing of products. To present their products and grow their client base, these businesses participate in numerous meetings. Orthomed, for example, took part in the 2017 SFA congress conducted in Marseille as well as the GEM congress conducted in Paris to display its' LIGASTIC ' ligaments.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever